Research Proposal Demo

Demo Mode
Start Your Own Project

Phase 1: Background & Literature

Define your research topic and PICO framework. The AI analyses your topic, then searches PubMed, ClinicalTrials.gov, Cochrane, and other databases to map the evidence landscape and identify existing reviews on your topic. This data feeds directly into your proposal rationale.

📚Background & Literature

PICO Framework

population

Treatment-naïve adults with advanced NSCLC (stage IIIB-IV)

intervention

PD-1/PD-L1 inhibitor immunotherapy

comparison

High vs low baseline gut microbiome diversity

outcomes

Objective response rate (RECIST 1.1), progression-free survival, overall survival

Research Gap

While checkpoint inhibitor immunotherapy has improved outcomes in advanced NSCLC, response rates remain suboptimal at 20-40%. Emerging evidence suggests the gut microbiota influences systemic immune responses and may predict immunotherapy efficacy, yet longitudinal studies are limited.

Significance

This study will establish the mechanistic link between microbiome diversity and immunotherapy response, enabling personalised treatment strategies.

Literature Landscape

847

Total studies

612

PubMed

89

ClinicalTrials.gov

6

Existing reviews

Feasibility Assessment

There is a substantial body of primary research (612 PubMed articles) examining the gut microbiome–immunotherapy axis. Six existing systematic reviews have been published, the most recent in 2024. However, none specifically focus on NSCLC with longitudinal microbiome sampling. The volume of new primary studies since the last review (>150 published after 2023) supports an updated, NSCLC-specific investigation. Recommend proceeding with a clearly defined scope distinguishing this from existing reviews.

Most Recent Reviews on This Topic

Gut microbiome and immunotherapy response: a systematic review and meta-analysis

Zhang Y, Chen L, Wu H et al.. J Immunother Cancer. 2024.

The role of gut microbiota in cancer immunotherapy: a systematic review

Liu M, Wang S, Fernandez J et al.. Clin Cancer Res. 2023.

Microbiome biomarkers for checkpoint inhibitor response: meta-analysis of observational studies

Park JH, Kim SK, Anderson R. Ann Oncol. 2023.

Strong evidence base — good candidate for a research proposal